The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
Open accessAbstract
BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Zoledronic acid is also indicated for the prevention of new clinical fractures in patients (both women and men) who have recently had a low-trauma (osteoporosis-related) hip fracture [58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationEffect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281
Updated Data on Proximal Femur Bone Mineral Levels of US Adults
Looker, A. C., Wahner, H. W., Dunn, W. L., Calvo, M. S., Harris, T. B., Heyse, S. P., Johnston Jr, C. C., & Lindsay, R. (1998) · Osteoporosis International · doi:10.1007/s001980050093 · Cited by 1,121
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 870
Self-citationRecovery From Hip Fracture in Eight Areas of Function
Magaziner, J. S., Hawkes, W., Hebel, J. R., Zimmerman, S. I., Fox, K. M., Dolan, M., Felsenthal, G., & Kenzora, J. E. (2000) · The Journals of Gerontology Series A · doi:10.1093/gerona/55.9.m498 · Cited by 742
Self-citationSiris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., & Silverman, S. L. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1013 · Cited by 703
EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN
Lung, R. M. C. C., Eusens, P. I. G., Aul, P., Iller, D. M., Ippel, H. A. Z., Ensen, W. I. G. B., Oux, C. H. R., Dami, S. I. A., Ogelman, I. G. F., Astell, R. I. E., et al. (2001) · Cited by 682
Prevention and Management of Osteoporosis
Compston, J. E. (1997) · Drugs · doi:10.2165/00003495-199753050-00001 · Cited by 487
Mortality and Locomotion 6 Months After Hospitalization for Hip Fracture
Hannan, E. L., Magaziner, J. S., WANG, J. J., Eastwood, E. A., Silberzweig, S. B., Gilbert, M. S., Morrison, R. S., McLaughlin, M. A., Orosz, G. M., & Siu, A. L. (2001) · JAMA · doi:10.1001/jama.285.21.2736 · Cited by 454
Self-citationUndertreatment of Osteoporosis in Men With Hip Fracture
Kiebzak, G. M., Beinart, G. A., Perser, K., Ambrose, C. G., Siff, S. J., & Heggeness, M. H. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2217 · Cited by 386
Huybrechts, K. F., Ishak, K. J., & Jaime, J. (2005) · Bone · doi:10.1016/j.bone.2005.10.022 · Cited by 344
Barette, M., Vanderschueren, D., Lips, P. T. A. M., Haentjens, P., Boonen, S., & Autier, P. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1515-z · Cited by 271
Self-citationAdachi, J. D., Ioannidis, G., Berger, C., Joseph, L., Παπαϊωάννου, Α., Pickard, L. E., Papadimitropoulos, E., Hopman, W. M., Poliquin, S., Prior, J. C., et al. (2001) · Osteoporosis International · doi:10.1007/s001980170017 · Cited by 260
Self-citationExcess mortality attributable to hip fracture in white women aged 70 years and older.
Magaziner, J. S., LYDICK, E. G., Hawkes, W., Fox, K. M., Zimmerman, S. I., Epstein, R. S., & Hebel, J. R. (1997) · American Journal of Public Health · doi:10.2105/ajph.87.10.1630 · Cited by 258
Self-citationFailure to diagnose and treat osteoporosis in elderly patients hospitalized with hip fracture
Kamel, H. K., Hussain, M. S., Tariq, S. H., Perry, H. M., & Morley, J. E. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00457-5 · Cited by 257
Standardization of Bone Mineral Density at Femoral Neck, Trochanter and Ward's Triangle
Lü, Y., Fuerst, T. P., Hui, S. L., & Genant, H. K. (2001) · Osteoporosis International · doi:10.1007/s001980170087 · Cited by 237
Hip fracture incidence among the old and very old: a population-based study of 745,435 cases.
Jacobsen, S. J., Goldberg, J., Miles, T. P., Brody, J. A., Stiers, W. M., & Rimm, A. A. (1990) · American Journal of Public Health · doi:10.2105/ajph.80.7.871 · Cited by 220
Prevention and management of osteoporosis
Eastell, R. (2017) · Medicine · doi:10.1016/j.mpmed.2017.06.004 · Cited by 214
INTERVENTIONS TO IMPROVE OSTEOPOROSIS TREATMENT FOLLOWING HIP FRACTURE
Gardner, M. J., Brophy, R. H., Demetrakopoulos, D., Koob, J., HONG, R., Rana, A. J., Lin, J. T., & Lane, J. M. (2005) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.d.02289 · Cited by 201
van Eijken, M., Tsang, S., Wensing, M., de Smet, P. A. G. M., & Grol, R. P. T. M. (2003) · Drugs & Aging · doi:10.2165/00002512-200320030-00006 · Cited by 184
The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies
Col�n-Emeric, C., Kuchibhatla, M., Pieper, C., Hawkes, W., Fredman, L., Magaziner, J., Zimmerman, S., & Lyles, K. W. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1460-x · Cited by 167
Self-citationBoonen, S., Rizzoli, R., Meunier, P. J., Stone, M. D., Nuki, G., Syversen, U., Lehtonen-Veromaa, M. K., Lips, P. T. A. M., Johnell, O., & Reginster, J. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1621-6 · Cited by 146
Self-citationUnderuse of osteoporosis medications in elderly patients with fractures
Solomon, D. H., Finkelstein, J. S., Katz, J. N., Mogun, H., & Avorn, J. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00357-7 · Cited by 142
Hip fracture mortality and morbidity--can we do better?
Davidson, C. W., Merrilees, M. J., WILKINSON, T. J., McKie, J., & Gilchrist, N. L. (2001) · PubMed · Cited by 103
Intravenous Zoledronic Acid in Postmenopausal Women With Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J., Kaufman, J., Jaeger, P., et al. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200301000-00020 · Cited by 93
Self-citationRandomized Trial to Improve Fracture Prevention in Nursing Home Residents
Colon-Emeric, C. S., Lyles, K. W., House, P., Levine, D. A., Schenck, A. P., Allison, J. J., Gorospe, J., Fermazin, M., Oliver, K., Curtis, J. R., et al. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.020 · Cited by 67
Self-citationColon-Emeric, C. S., Caminis, J. N., Suh, T. T., Pieper, C. F., Janning, C. D., Magaziner, J. S., Adachi, J. D., Rosario-Jansen, T., Mesenbrink, P. G., Horowitz, Z., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003683 · Cited by 38
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- Davidson CW, 2001, N Z Med J, 114, 329
- 2003, World Health Organ Tech Rep Ser, 921, 1
Cited by
Sorted by citations
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
“Zoledronic acid is also indicated for the prevention of new clinical fractures in patients (both women and men) who have recently had a lowtrauma (osteoporosis-related) hip fracture [58].”
BackgroundEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C. C., Rizzoli, R., & Reginster, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,993
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,790
Papaioannou, A., Morin, S. N., Cheung, A. M., Atkinson, S. A., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A. B., Jamal, S. A., Kaiser, S., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,768
Metadata
- Authors
- Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
- Affiliations
- Veterans Health Administration (US)
- University of Maryland, Baltimore (US)
- McMaster University (CA)
- Duke Medical Center (US)
- Hvidovre Hospital (DK)
- Oslo University Hospital (NO)
- Savient Pharmaceuticals (United States) (US)
- Novartis (Switzerland) (CH)
- KU Leuven (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11
- Volume
- 357
- Issue
- 18
- Pages
- 1799-1809
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2324066
- OpenAlex
- W2163830908
- Cited by
- 2,003
- References
- 35
- Citations by year
- 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
- FWCI
- 160.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- PubMed Central (acceptedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Savient Pharmaceuticals
- Novo Nordisk
- Servier
- National Institute on Aging (K23AG024787)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
